DPDaily Peptide

The Data · Tracker

Regulatory Status Tracker

All 22 compounds. Current regulatory status and evidence tier. Updated editorially as the landscape shifts.

← Back to Decoded

Regulatory Pipeline · left = less oversight · right = more

GREY MARKET

INVESTIGATIONAL

COMPOUNDING

FDA APPROVED

Evidence Tier

PHASE 3+PHASE 2PHASE 1PRECLINICAL

// WEIGHT LOSS

Semaglutide

FDA APPROVED

PHASE 3+
Tirzepatide

FDA APPROVED

PHASE 3+
Retatrutide

INVESTIGATIONAL

PHASE 3+

// GH SLEEP

Tesamorelin

FDA APPROVED

PHASE 3+
Sermorelin

COMPOUNDING

PHASE 3+
CJC-1295 no DAC

GREY MARKET

PHASE 1
Ipamorelin

GREY MARKET

PHASE 1
DSIP

GREY MARKET

PRECLINICAL

// RECOVERY

BPC-157

GREY MARKET

PHASE 2
TB-500

GREY MARKET

PRECLINICAL
GHK-CuPhase 3 data is topical wound healing only · Injectable/systemic use has Phase 2-level evidence · Category 2 removal Apr 2026 · PCAC review pending

GREY MARKET

PHASE 2

// IMMUNE

Thymosin α-1Not FDA approved · Internationally approved as Zadaxin in 35+ countries

GREY MARKET

PHASE 3+
KPV

GREY MARKET

PRECLINICAL
LL-37

GREY MARKET

PHASE 1

// NOOTROPIC

SemaxRussian prescription approval · Non-GCP data · No Western trials

GREY MARKET

PRECLINICAL
SelankRussian prescription approval · Non-GCP data · No Western trials

GREY MARKET

PRECLINICAL
Dihexa

GREY MARKET

PRECLINICAL

// LONGEVITY

MOTS-c

GREY MARKET

PRECLINICAL
EpitalonKhavinson group data only · No Western clinical trials

GREY MARKET

PRECLINICAL
SS-31Phase 3 complete (TAZPOWER) · No FDA approval · Orphan Drug + Breakthrough Therapy designation

INVESTIGATIONAL

PHASE 3+

// MELANOCORTIN (TANNING / LIBIDO)

Melanotan I

FDA APPROVED

PHASE 3+
Melanotan II

GREY MARKET

PHASE 1

Regulatory status reflects editorially verified information as of each compound profile date. Not legal or medical advice. Status changes as the FDA acts.

← The Data